Financials Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.58 USD +2.60% Intraday chart for Lexicon Pharmaceuticals, Inc. -4.24% +3.27%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 441 481.2 586.6 360.5 373.4 389.1 - -
Enterprise Value (EV) 1 639.1 354.9 499.9 360.5 373.4 389.1 389.1 389.1
P/E ratio 3.58 x -6.45 x -6.57 x -3.08 x -1.94 x -2.22 x -2.49 x -4.33 x
Yield - - - - - - - -
Capitalization / Revenue 1.37 x 20.1 x 1,969 x 2,593 x 310 x 15.1 x 5.02 x 2.28 x
EV / Revenue 1.37 x 20.1 x 1,969 x 2,593 x 310 x 15.1 x 5.02 x 2.28 x
EV / EBITDA 2.54 x -10.7 x -6.76 x -3.59 x -2.18 x -2.32 x -3.09 x -
EV / FCF 3,877,618 x -3,363,760 x -6,648,485 x - - - - -
FCF Yield 0% -0% -0% - - - - -
Price to Book 3.77 x 3.09 x 5.17 x - - - - -
Nbr of stocks (in thousands) 106,272 140,704 148,896 188,726 244,025 246,237 - -
Reference price 2 4.150 3.420 3.940 1.910 1.530 1.580 1.580 1.580
Announcement Date 3/12/20 3/10/21 2/28/22 3/2/23 3/11/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 322.1 24 0.298 0.139 1.204 25.81 77.52 170.5
EBITDA 1 173.7 -44.87 -86.8 -100.3 -171.2 -168 -126 -
EBIT 1 141.4 -47.8 -87.09 -100.8 -171.8 -200.5 -188.2 -106.1
Operating Margin 43.92% -199.21% -29,224.83% -72,489.21% -14,264.95% -776.82% -242.77% -62.23%
Earnings before Tax (EBT) 1 124.1 -58.57 -87.76 -101.9 -175.6 -199.4 -193.4 -105.6
Net income 1 130.1 -58.57 -87.76 -101.9 -175.6 -199.4 -193.4 -105.6
Net margin 40.4% -244.11% -29,448.99% -73,341.01% -14,585.3% -772.42% -249.47% -61.93%
EPS 2 1.160 -0.5300 -0.6000 -0.6200 -0.7900 -0.7105 -0.6340 -0.3650
Free Cash Flow 113.7 -143.1 -88.24 - - - - -
FCF margin 35.31% -596.19% -29,610.07% - - - - -
FCF Conversion (EBITDA) 65.47% - - - - - - -
FCF Conversion (Net income) 87.4% - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/12/20 3/10/21 2/28/22 3/2/23 3/11/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - 0.014 0.037 0.035 0.039 0.028 0.024 0.317 0.162 0.702 1.368 2.97 9.386 12.05 20.97
EBITDA 1 -22.86 -25.22 -23.27 - - - - - - -46.59 -50.73 -46.04 -39.65 - -
EBIT 1 -22.96 -25.33 -23.38 -24.01 -23.1 -30.28 -31.14 -44.24 -49.63 -46.74 -50.93 -50.61 -46.59 -48.58 -41.18
Operating Margin - -180,928.57% -63,189.19% -68,591.43% -59,217.95% -108,135.71% -129,758.33% -13,955.84% -30,636.42% -6,657.69% -3,724.06% -1,703.93% -496.35% -402.97% -196.38%
Earnings before Tax (EBT) 1 -23.12 -25.61 -23.48 -24.59 -23.39 -30.49 -31.93 -44.9 -50.52 -48.24 -51.71 -50.7 -46.36 -48.24 -41.18
Net income 1 -23.12 -25.61 -23.48 -24.59 -23.39 -30.49 -31.93 -44.9 -50.52 -48.24 -51.71 -50.7 -46.36 -48.24 -41.18
Net margin - -182,935.71% -63,448.65% -70,248.57% -59,966.67% -108,907.14% -133,058.33% -14,165.3% -31,188.27% -6,872.36% -3,780.79% -1,707.15% -493.99% -400.21% -196.38%
EPS 2 -0.1600 -0.1700 -0.1600 -0.1600 -0.1300 -0.1600 -0.1700 -0.2200 -0.2100 -0.2000 -0.1967 -0.1800 -0.1667 -0.1633 -0.1600
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/28/22 5/5/22 8/2/22 11/9/22 3/2/23 5/2/23 8/3/23 11/8/23 3/11/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 198 - - - - - - -
Net Cash position - 126 86.7 - - - - -
Leverage (Debt/EBITDA) 1.14 x - - - - - - -
Free Cash Flow 114 -143 -88.2 - - - - -
ROE (net income / shareholders' equity) 287% -139% -65% -88.4% -167% -1,181% - -
ROA (Net income/ Total Assets) 37.1% -18.8% -51.5% - - - - -
Assets 1 350.9 310.8 170.3 - - - - -
Book Value Per Share 1.100 1.110 0.7600 - - - - -
Cash Flow per Share - - - - - - - -
Capex - - 1.22 - - - - -
Capex / Sales - - 409.73% - - - - -
Announcement Date 3/12/20 3/10/21 2/28/22 3/2/23 3/11/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.58 USD
Average target price
5.333 USD
Spread / Average Target
+237.55%
Consensus
  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. Financials Lexicon Pharmaceuticals, Inc.